Onkologie. 2026:20(3):146-149 | DOI: 10.36290/xon.2026.027
Intensification of systemic therapy in a patient with de novo metastatic hormone-sensitive prostate cancer
- Onkologické oddělení, Nemocnice České Budějovice
The treatment landscape for metastatic hormone-sensitive prostate cancer has undergone significant shifts in recent years. The current standard of care has transitioned toward combination regimens integrating androgen deprivation therapy with androgen receptor signaling inhibitors, and potentially docetaxel-based chemotherapy. This intensified approach facilitates a delay in disease progression to the castration-resistant stage and significantly extends overall survival. The presented case report documents the clinical application of a "triplet therapy" (ADT, darolutamide, docetaxel) in a patient diagnosed with high-risk de novo metastatic prostate cancer.
Keywords: metastatic hormone-sensitive prostate cancer, intensification of systemic therapy, darolutamide, docetaxel, case report.
Accepted: June 15, 2026; Published: July 1, 2026 Show citation
References
- Systém pro vizualizaci onkologických dat - výstup dat: karcinom prostaty, incidence, mortalita, relativní přežití (muži, Česká republika) [online]. SVOD; 2023 [cit. 3. 1. 2026]. Available from: https://www.svod.cz.
- Talwar V, Kalra K, Kapoor A, et al. Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review. Current Oncology. 2025;32(8):437. doi: 10.3390/curroncol32080437.
Go to original source... 
Go to PubMed... - Souhrny údajů o přípravku inhibitorů androgenního receptoru (abirateron-acetát, apalutamid, enzalutamid, darolutamid) a docetaxel [online]. Státní ústav pro kontrolu léčiv [cit. 10. 1. 2026]. Available from: https://www.sukl.cz.
- McManus HD, Armstrong AJ. The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2023;41:3576-3579. doi: 10.1200/JCO.23.00323. Go to original source...
- Sweeney CJ, Chen Y, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737-746. doi: 10.1056/NEJMoa1503747. Go to original source... Go to PubMed...
- Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352-360. doi: 10.1056/NEJMoa1704174. Go to original source... Go to PubMed...
- Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142. doi: 10.1056/NEJMoa2119115. Go to original source... Go to PubMed...
- Hussain M, Tombal B, Saad F, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023;41:3595-3607. doi: 10.1200/JCO.23.00041. Go to original source... Go to PubMed...
- Saad F, Hussain M, Tombal B, et al. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High or Low volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. Eur Urol. 2024;86:340-342. doi: 10.1016/j.eururo.2024.03.036. Go to original source... Go to PubMed...